JP2012521428A - 疼痛治療用のｐ２ｘ３受容体アンタゴニスト - Google Patents

疼痛治療用のｐ２ｘ３受容体アンタゴニスト Download PDF

Info

Publication number
JP2012521428A
JP2012521428A JP2012502097A JP2012502097A JP2012521428A JP 2012521428 A JP2012521428 A JP 2012521428A JP 2012502097 A JP2012502097 A JP 2012502097A JP 2012502097 A JP2012502097 A JP 2012502097A JP 2012521428 A JP2012521428 A JP 2012521428A
Authority
JP
Japan
Prior art keywords
chr
alkyl
mmol
heterocyclyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012502097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521428A5 (https=
Inventor
バーギー，クリストフアー・エス
ドン，ジエンウー・ジエイ
グエン，デイエム・エヌ
パオン，ダニエル・ブイ
ポテイジヤー，クレツグ・エム
スタウフアー，シヨーン・アール
シーガーデル，キヤロリン
ノムランド，アシユリー
リム，ジヨン・ジエイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2012521428A publication Critical patent/JP2012521428A/ja
Publication of JP2012521428A5 publication Critical patent/JP2012521428A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012502097A 2009-03-23 2010-03-15 疼痛治療用のｐ２ｘ３受容体アンタゴニスト Pending JP2012521428A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21084509P 2009-03-23 2009-03-23
US61/210,845 2009-03-23
PCT/US2010/027286 WO2010111058A1 (en) 2009-03-23 2010-03-15 P2x3, receptor antagonists for treatment of pain

Publications (2)

Publication Number Publication Date
JP2012521428A true JP2012521428A (ja) 2012-09-13
JP2012521428A5 JP2012521428A5 (https=) 2013-05-02

Family

ID=42781385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012502097A Pending JP2012521428A (ja) 2009-03-23 2010-03-15 疼痛治療用のｐ２ｘ３受容体アンタゴニスト

Country Status (6)

Country Link
US (1) US9238647B2 (https=)
EP (1) EP2410857B1 (https=)
JP (1) JP2012521428A (https=)
AU (1) AU2010229142A1 (https=)
CA (1) CA2755680A1 (https=)
WO (1) WO2010111058A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532832A (ja) * 2009-06-22 2012-12-20 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３および／またはｐ２ｘ２／３アンタゴニストとしての、新規なインドール、インダゾールおよびベンゾイミダゾールアリールアミド
JP2016506935A (ja) * 2013-01-31 2016-03-07 ネオメド・インスティチュート イミダゾピリジン化合物及びその使用
WO2016088838A1 (ja) * 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
JP2016540027A (ja) * 2013-12-16 2016-12-22 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー Ｐ２ｘ３および／またはｐ２ｘ２／３化合物ならびに方法
WO2018168898A1 (ja) * 2017-03-15 2018-09-20 大日本住友製薬株式会社 新規ベンズイミダゾロン化合物およびその医薬用途

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009561A (es) 2008-02-29 2010-09-24 Renovis Inc Compuestos amida, composiciones y usos de los mismos.
CA2737038A1 (en) 2008-09-18 2010-03-25 Evotec Ag Amide compounds, compositions and uses thereof
US20100273805A1 (en) * 2009-04-23 2010-10-28 Astrazeneca Ab Sulphide bridged derivatives as modulators of mglur5 733
CN103261195B (zh) * 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl) * 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
PL2678329T3 (pl) * 2011-02-25 2016-06-30 Array Biopharma Inc Związki triazolopirydyny jako inhibitory kinaz pim
EP2905282A1 (en) 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
WO2016036633A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
US9877957B2 (en) 2014-09-05 2018-01-30 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
WO2016036638A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
WO2017209267A1 (ja) * 2016-06-03 2017-12-07 塩野義製薬株式会社 プリン誘導体
WO2018093698A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
AU2017360939B2 (en) 2016-11-18 2022-03-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
CN111670189A (zh) 2018-01-31 2020-09-15 爱尔兰詹森科学公司 对rsv具有活性的环烷基取代的吡唑并嘧啶
MA52348A (fr) 2018-04-23 2021-03-03 Janssen Sciences Ireland Unlimited Co Composés hétéroaromatiques ayant une activité contre vrs
WO2020256430A1 (ko) * 2019-06-19 2020-12-24 주식회사 엘지화학 인돌 또는 인다졸 화합물의 제조방법
EP4103572A4 (en) 2020-02-14 2024-03-06 Bellus Health Cough Inc. MAKING A P2X3 ANTAGONIST
WO2022063205A1 (zh) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
CN115322143B (zh) * 2022-07-21 2023-07-14 安徽德诺医药股份有限公司 一种4-哌啶甲酸叔丁酯盐酸盐的制备方法
WO2024137671A1 (en) * 2022-12-20 2024-06-27 Exelixis, Inc. Compounds that inhibit pkmyt1

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048697A1 (en) * 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
WO2000012074A2 (en) * 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
WO2003000682A1 (en) * 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
WO2007020194A1 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Piperidine and piperazine derivatives as p2x3 antagonists
WO2007069053A1 (en) * 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007086080A2 (en) * 2006-01-30 2007-08-02 Glenmark Pharmaceuticals Limited NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2008027812A2 (en) * 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
WO2008082490A2 (en) * 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
WO2008085302A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517221A (en) 1999-08-19 2004-01-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20080033006A1 (en) * 2004-01-26 2008-02-07 Altana Pharma Ag 1,2,4-Triazolo[ 1,5-A] Pyridines as Gastric Acid Secretion Inhibitors
EP1863635A2 (en) 2005-03-24 2007-12-12 Arrow Coated Products Limited Combined multi-layered water soluble film and process for producing the same
MX2007013595A (es) 2005-05-04 2008-01-24 Renovis Inc Compuestos heterociclicos fusionados y composiciones y usos de estos.
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
EP1896011A1 (en) 2005-06-28 2008-03-12 AstraZeneca AB New use
JP4850914B2 (ja) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン
WO2007041087A2 (en) 2005-09-30 2007-04-12 Merck & Co., Inc. Nucleic acids encoding a functional mammalian purinoreceptor, p2x3, methods of production and use thereof
AU2006311729A1 (en) * 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
EP2592070B1 (en) 2006-06-29 2016-08-31 F. Hoffmann-La Roche AG Tetrazole-substituted arylamides
FR2903107B1 (fr) 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
CA2703909A1 (en) 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
AU2008319309B2 (en) 2007-10-31 2012-09-06 Merck Sharp & Dohme Llc P2X3 receptor antagonists for treatment of pain
ES2534199T3 (es) 2008-10-31 2015-04-20 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
WO2010059836A1 (en) * 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US8476457B2 (en) * 2009-06-22 2013-07-02 Roche Palo Alto Llc Indole, indazole and benzimidazole arylamides as P2X3 and P2X2/3 antagonists

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048697A1 (en) * 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
WO2000012074A2 (en) * 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
WO2003000682A1 (en) * 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
WO2007020194A1 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Piperidine and piperazine derivatives as p2x3 antagonists
WO2007069053A1 (en) * 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007086080A2 (en) * 2006-01-30 2007-08-02 Glenmark Pharmaceuticals Limited NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2008027812A2 (en) * 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
WO2008082490A2 (en) * 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
WO2008085302A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532832A (ja) * 2009-06-22 2012-12-20 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３および／またはｐ２ｘ２／３アンタゴニストとしての、新規なインドール、インダゾールおよびベンゾイミダゾールアリールアミド
JP2016506935A (ja) * 2013-01-31 2016-03-07 ネオメド・インスティチュート イミダゾピリジン化合物及びその使用
JP2016540027A (ja) * 2013-12-16 2016-12-22 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー Ｐ２ｘ３および／またはｐ２ｘ２／３化合物ならびに方法
JP2020007322A (ja) * 2013-12-16 2020-01-16 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー Ｐ２ｘ３および／またはｐ２ｘ２／３化合物ならびに方法
JP7182526B2 (ja) 2013-12-16 2022-12-02 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー Ｐ２ｘ３および／またはｐ２ｘ２／３化合物ならびに方法
US11685736B2 (en) 2013-12-16 2023-06-27 Abs Development 1, Inc. P2X3 and/or P2X2/3 compounds and methods
WO2016088838A1 (ja) * 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
WO2018168898A1 (ja) * 2017-03-15 2018-09-20 大日本住友製薬株式会社 新規ベンズイミダゾロン化合物およびその医薬用途
KR20190129070A (ko) * 2017-03-15 2019-11-19 다이니뽄 스미토모 세이야쿠 가부시키가이샤 신규 벤즈이미다졸론 화합물 및 그의 의약 용도
JPWO2018168898A1 (ja) * 2017-03-15 2020-01-16 大日本住友製薬株式会社 新規ベンズイミダゾロン化合物およびその医薬用途
JP7175878B2 (ja) 2017-03-15 2022-11-21 住友ファーマ株式会社 新規ベンズイミダゾロン化合物およびその医薬用途
KR102606737B1 (ko) 2017-03-15 2023-11-24 스미토모 파마 가부시키가이샤 신규 벤즈이미다졸론 화합물 및 그의 의약 용도

Also Published As

Publication number Publication date
WO2010111058A1 (en) 2010-09-30
US9238647B2 (en) 2016-01-19
EP2410857A1 (en) 2012-02-01
US20120064181A1 (en) 2012-03-15
EP2410857B1 (en) 2014-01-29
CA2755680A1 (en) 2010-09-30
EP2410857A4 (en) 2012-10-31
AU2010229142A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
JP2012521428A (ja) 疼痛治療用のｐ２ｘ３受容体アンタゴニスト
EP2358371B1 (en) P2x3, receptor antagonists for treatment of pain
EP2411001B1 (en) P2x3, receptor antagonists for treatment of pain
JP5552430B2 (ja) 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
EP2410858B1 (en) P2x3 receptor antagonists for treatment of pain
JP6197125B2 (ja) 化合物の組成物およびその使用
JP5099005B2 (ja) ヘテロ化合物
EP2215049B1 (en) P2x3, receptor antagonists for treatment of pain
AU2012213860A1 (en) Bicyclic heteroaryl compounds as GPR119 receptor agonists
WO2019205983A1 (zh) 氧杂螺环类化合物及其制备方法和用途
TW201945355A (zh) 作為crhr2拮抗劑之稠合環狀脲衍生物
EA037264B1 (ru) Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство
JP6905988B2 (ja) Ｅａａｔ３阻害剤としてのピラゾール−ピリジン誘導体
JP2024509142A (ja) Ｈｃｎ２調節剤として有用なピリミジン又はピリジン誘導体

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141028